Replies to post #256484 on Biotech Values

[DewDiligence]

EXAS presents data_for minimal-residual-disease—(MRD)—diagnostic for TNBC:

https://www.businesswire.com/news/home/20251211912129/en/Exact-Sciences-the-NSABP-Foundation-and-the-German-Breast-Group-Present-Results-for-the-Oncodetect-MRD-Test-in-Early-Triple-Negative-Breast-Cancer-at-SABCS

EXAS is being acquired by ABT (#msg-176971675).

[DewDiligence]

(ABT)—EXAS reports 4Q25 results:

https://www.businesswire.com/news/home/20260213963431/en/Exact-Sciences-Announces-Record-Fourth-Quarter-and-Full-Year-2025-Results

4Q25 sales were $878M, +23% YoY. No CC because of the pending acquisition by ABT.

EXAS shareholders will vote on the acquisition 2/20/26, but approval is a fait accompli.